Septerna (NASDAQ:SEPN) Rating Lowered to Equal Weight at Wells Fargo & Company

Wells Fargo & Company cut shares of Septerna (NASDAQ:SEPN) from an overweight rating to an equal weight rating in a report issued on Tuesday, MarketBeat.com reports. They currently have $14.00 price objective on the stock, down from their previous price objective of $43.00.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price for the company. TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Price Performance

Shares of Septerna stock opened at $5.89 on Tuesday. The stock’s 50 day moving average is $18.11. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99.

Institutional Investors Weigh In On Septerna

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC acquired a new position in shares of Septerna in the fourth quarter valued at $25,000. New York State Common Retirement Fund acquired a new position in shares of Septerna in the fourth quarter valued at $32,000. Legal & General Group Plc acquired a new position in shares of Septerna in the fourth quarter valued at $42,000. Summit Investment Advisors Inc. acquired a new position in shares of Septerna in the fourth quarter valued at $45,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Septerna in the fourth quarter valued at $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.